Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Roivant Sciences Ltd (ROIV)

Roivant Sciences Ltd (ROIV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026 GlobeNewswire - Thu Aug 6, 6:00AM CDT

All IMVT-1402 clinical development timelines remain on track, including ongoing studies in Graves’ disease (GD), myasthenia gravis (MG), chronic inflammatory demyelinating polyneuropathy (CIDP), difficult-to-treat...

IMVT : 44.35 (-1.36%)
ROIV : 36.84 (-1.50%)
Roivant Reports Financial Results for the First Quarter Ended June 30, 2026, and Provides Business Update GlobeNewswire - Thu Aug 6, 6:00AM CDT

Commercial preparations for brepocitinib in dermatomyositis (DM) are progressing well and on track for launch by the end of September 2026; topline data from Phase 3 study in non-infectious uveitis (NIU)...

ROIVW : 2.75 (-3.85%)
ROIV : 36.84 (-1.50%)
Priovant Announces First Patients Enrolled in Phase 3 Study (BEACON+) of Brepocitinib in Cutaneous Sarcoidosis (CS) GlobeNewswire - Thu Aug 6, 6:00AM CDT

CS is a highly morbid, chronic, and disfiguring condition with no approved therapies Brepocitinib is the first investigational therapy to generate a positive result in a placebo-controlled CS study (Phase...

ROIVW : 2.75 (-3.85%)
ROIV : 36.84 (-1.50%)
Roivant's Pipeline Transparency Test Arrives as Brepocitinib Nears Its First Commercial Moment Barchart - Wed Aug 5, 4:28PM CDT

Barchart Research What to Expect from ROIV Earnings ROIV Generated August 5, 2026 Current Price $34.60 EPS Estimate $$-0.45 Consensus Rating Strong Buy Average Move 7.24% Roivant's Pipeline Transparency...

ROIV : 36.84 (-1.50%)
Immunovant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026 GlobeNewswire - Thu Jul 23, 3:05PM CDT

DURHAM, N.C., July 23, 2026 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq:  IMVT ) today announced that it will report its financial results for the first quarter ended June 30, 2026 on Thursday, August...

IMVT : 44.35 (-1.36%)
ROIV : 36.84 (-1.50%)
Roivant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026 GlobeNewswire - Thu Jul 23, 3:05PM CDT

BASEL, Switzerland and LONDON and NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday,...

ROIVW : 2.75 (-3.85%)
ROIV : 36.84 (-1.50%)
MarketBeat.com
Roivant Sciences Q4 Earnings Call Highlights MarketBeat - Wed May 20, 9:07AM CDT

Roivant Sciences (NASDAQ:ROIV) executives used the company’s fourth-quarter earnings call to highlight new open-label data for IMVT-1402 in difficult-to-treat rheumatoid arthritis, upcoming pulmonary...

ROIV : 36.84 (-1.50%)
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update GlobeNewswire - Wed May 20, 6:00AM CDT

IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA); Immunovant...

ROIVW : 2.75 (-3.85%)
ROIV : 36.84 (-1.50%)
Roivant's Cash Runway Gets Its Clearest Disclosure in a Year Barchart - Tue May 19, 4:04PM CDT

Barchart Research What to Expect from ROIV Earnings ROIV Generated May 19, 2026 Current Price $28.20 EPS Estimate $$-0.38 Consensus Rating Strong Buy Average Move 5.78% Roivant's Cash Runway Gets Its Clearest...

ROIV : 36.84 (-1.50%)
Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provide Business Update on Wednesday, May 20, 2026 GlobeNewswire - Mon May 11, 3:05PM CDT

BASEL, Switzerland and LONDON and NEW YORK, May 11, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Wednesday,...

ROIVW : 2.75 (-3.85%)
ROIV : 36.84 (-1.50%)

Barchart Exclusives

Bill Ackman Loves This Dividend Stock, But You Should Give It a Pass Barchart - Thu Aug 20, 6:30PM CDT
Bill Ackman's Pershing Square has held shares of Restaurant Brands International for over a decade. QSR stock has a healthy dividend yield of 3.4% but does not look like a compelling buy. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.